Latest GLP-1 Therapies Research Papers | Page 12 | OpenScience.ink

3 weeks ago • JAMA psychiatry

Patient-Reported Changes in Alcohol Use After Starting GLP-1 MedicationPatient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation.

🥇 Top 1% JournalArticle

3 weeks ago • The lancet. Psychiatry

Starting GLP-1 drugs and the risk of psychiatric hospital visits in US adults with schizophrenia and type 2 diabetesGLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data.

🥇 Top 1% JournalObservational Study

3 weeks ago • Acta diabetologica

Risk of repeated sudden pancreas inflammation with GLP-1 receptor drugs after previous pancreas inflammation: a systematic reviewRisk of recurrent acute pancreatitis with GLP-1 receptor agonists after prior pancreatitis: a systematic review.

Article

3 weeks ago • Journal of molecular histology

Liraglutide helps obesity-related type 2 diabetes by changing immune cell cholesterol use and gene activity to boost anti-inflammatory cells and fat burningLiraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation.

📖 Top 30% JournalArticle

3 weeks ago • Clinical pharmacokinetics

Detailed Review of Efsubaglutide Alfa's Drug Actions and EffectsEfsubaglutide Alfa: A Comprehensive Pharmacological Review.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in medicine

GLP-1 receptor agonists for fatty liver disease linked to metabolic problems: plan for a review of clinical trialsGLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials.

📖 Top 20% JournalArticle

3 weeks ago • Frontiers in medicine

Different eye safety effects of glucagon-like peptide-1 receptor drugs based on their chemical differencesDivergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework.

📖 Top 20% JournalArticle

3 weeks ago • Cardiac failure review

Glucagon-like Peptide-1 and New Heart and Metabolism Treatments in Heart Failure with Normal Pumping: Connecting Molecular Actions to Patient ResultsGlucagon-like Peptide-1-based and Emerging Cardiometabolic Therapies in Heart Failure with Preserved Ejection Fraction: Linking Molecular Mechanisms to Clinical Outcomes.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in endocrinology

Expert Recommendations for Long-Term Use of GLP-1 Medicines in Treating ObesityLong-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice.

🎖️ Top 10% JournalPractice Guideline

3 weeks ago • Annals of medicine and surgery (2012)

Weight-loss drugs that may reduce drinking: using GLP-1 receptor activators as targeted therapy for alcohol use disorderWhen weight-loss drugs reduce drinking: glucagon-like peptide-1 receptor agonists as phenotype-enriched harm-reduction therapy for alcohol use disorder.

Editorial

3 weeks ago • Translational andrology and urology

Comparison of diabetes drugs and their links to new and repeated kidney stonesSodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review.

📖 Top 30% JournalArticle

3 weeks ago • Frontiers in endocrinology

Continuous glucose levels after stopping diabetes-related weight loss drugs: clues about metabolism and keeping weight offContinuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in endocrinology

Pancreatic and bile duct safety concerns linked to GLP-1 receptor agonists and tirzepatide based on FDA report analysisPancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports.

🎖️ Top 10% JournalArticle

3 weeks ago • Annals of medicine and surgery (2012)

New drug treatment for obesity: oral semaglutide for weight lossAdvances in pharmacologic management of obesity: oral semaglutide for weight management.

Article

3 weeks ago • Diabetes, obesity & metabolism

Effects of GLP-1RA and SGLT2 Inhibitor Treatments on Fat Around the Kidneys in Chronic Kidney Disease PatientsThe Effects of GLP-1RA-Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD Patients.

Article

3 weeks ago • Otolaryngologic clinics of North America

Thyroid Problems in the Age of Obesity and Diabetes Drugs That Lower Blood SugarThyroid Disease in the Era of Obesity and Glucagon-Like-Peptide-1 Agonists.

📖 Top 50% JournalArticle

3 weeks ago • Journal of obesity & metabolic syndrome

Key rules and limits in making obesity and metabolism policies in Asian health systemsHealth Policy for Obesity and Metabolic Syndrome in Asian Health Systems: Three Design Principles, Three Binding Constraints, and the Governance That Decides between Them.

🥉 Top 5% JournalArticle

3 weeks ago • The Journal of clinical endocrinology and metabolism

Tirzepatide’s effects on heart and kidney health markers and physical ability in heart failureEffects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.

🥉 Top 5% JournalArticle

3 weeks ago • The Journal of cardiovascular nursing

Nurse Practitioner-Led Use of Diabetes Drugs to Treat Obesity-Related Heart Failure with Normal Pump Function: A Clinical Effectiveness StudyNurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study.

📖 Top 50% JournalArticle

3 weeks ago • JPGN reports

Tirzepatide treatment in teenagers with fatty liver disease linked to metabolism problems: A case seriesTirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series.

Article

3 weeks ago • BMJ medicine

Patient preferences and challenges starting newer diabetes medicines in adults with type 2 diabetesValues, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.

Systematic Review

3 weeks ago • Journal of Ayurveda and integrative medicine

Long-term metabolism control with GLP-1 receptor drugs: Combining Ayurvedic and medical viewsLong-term metabolic regulation in the era of GLP-1 receptor agonists: An integrative review of Ayurvedic and biomedical perspectives.

📖 Top 50% JournalArticle

3 weeks ago • European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Hearing and balance side effects reported for GLP-1 receptor drugs: A study using FDA safety dataAudiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data.

📖 Top 30% JournalArticle

3 weeks ago • Aesthetic plastic surgery

Facial Changes Linked to GLP-1 Receptor Agonists Beyond Their Weight Loss EffectsBeyond Weight Loss: Facial Remodeling Associated with GLP-1 Receptor Agonists-A Systematic Review and Therapeutic Framework.

📖 Top 20% JournalArticle

3 weeks ago • Annals of cardiac anaesthesia

GLP-1 Receptor Agonists with Insulin Compared to Insulin Alone for Blood Sugar Control Around Heart Surgery in Type 2 DiabetesGLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.

Systematic Review

3 weeks ago • Journal of agricultural and food chemistry

Short-Chain Fatty Acids May Slow DPP-IV Enzyme to Help Keep GLP-1 Stable and Support Metabolic HealthShort-Chain Fatty Acids as Endogenous Inhibitors of DPP-IV Enzyme: Implications in GLP-1 Stability and Metabolic Health.

📖 Top 20% JournalArticle

3 weeks ago • Annals of clinical and translational neurology

How Diabetes May Cause Thinking Problems and New Treatment ApproachesDiabetes-Associated Cognitive Impairment: Pathophysiology and Emerging Therapies.

🎖️ Top 10% JournalArticle

3 weeks ago • IBRO neuroscience reports

How Hormones Control Appetite and Energy Balance in Metabolic DisordersNeuroendocrine regulation of appetite and energy balance in metabolic disorders.

📖 Top 30% JournalArticle

3 weeks ago • Diabetes, obesity & metabolism

Immediate Effects of Acarbose and Canagliflozin, Alone and Together, on Blood Sugar and Gut Hormone After Meals in People with Low Blood Sugar After Weight SurgeryAcute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP-1 and Glycaemic Responses in Post-Bariatric Hypoglycaemia: A Randomised Crossover Study.

Article

3 weeks ago • Advances in therapy

Patterns of Blood Sugar Treatments That Protect Heart and Kidney in Type 2 Diabetes Based on Real-World Patient GroupsCardiorenal Protective Glucose-Lowering Treatment Patterns in Type 2 Diabetes Mellitus Based on a Real-World Study: A Clinical Phenotype Cluster Analysis.

📖 Top 20% JournalArticle

← prevpage 12 of 16next →